A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus.

Publication date: Jun 23, 2023

The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality rates. Here, we conjugated recombinant receptor binding domain (RBD) of SARS-CoV-2 spike protein onto inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection. This double-hit vaccine (Flu-RBD) not only induced protective immunities against SARS-CoV-2 but also remained functional as a flu vaccine. The Flu core improved the retention and distribution of Flu-RBD vaccine in the draining lymph nodes, with enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD efficiently protected animals against viral infection. Furthermore, Flu-RBD VLP elicited a strong neutralization activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID-19, influenza A, and coinfection.

Open Access PDF

Concepts Keywords
Immunities Based
Influenza Conjugated
Live Cov
Mice Covid
Pseudovirus Double


Type Source Name
disease MESH influenza
disease VO vaccine
drug DRUGBANK Influenza A virus
disease VO Viruses
disease MESH COVID-19 pandemic
disease IDO infectivity
pathway REACTOME SARS-CoV-2 Infection
disease MESH viral infection
pathway KEGG Influenza A
disease MESH coinfection

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *